Search This Blog

Monday, August 6, 2018

BioCryst granted FDA Fast Track Designation for Angioderma Med


BioCryst announced that the company has been granted Fast Track Designation by the U.S. FDA for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)